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One of the key aspects of any strategy for gene therapy is the
system used for gene delivery, and several of these were
individually reviewed. Currently, virus-based (particularly
retrovirus) delivery systems are most numerous. These in
general use well-established technology based on Moloney
murine leukaemia virus, and this system is the basis of the
majority of the current attempts in therapeutic delivery.
Although apparently satisfactory in many situations, the cur-
rent generation of vectors suffers from a number of disadvan-
tages such as relatively poor infectivity for human cells and
the possibility of reactivation of endogenous replication-
competent retroviral genetic elements. Mary Collins
(London) described experiments aimed at circumventing
these difficulties by utilising vectors derived from retroviruses
of other species. Retroviruses infect cells via specific cell-
surface receptors, which fall into eight groups. Feline
leukaemia virus subgroup B, Gibbon ape leukaemia virus
and Simian sarcoma-associated virus all share a common
receptor and show promise as second-generation retroviral
vector systems.
Among the DNA viruses, adenovirus is being vigorously
investigated as a vector. Although natural adenovirus infec-
tion is associated with mild respiratory disease, administra-
tion of live virus to humans has been successfully employed
in a vaccine context and has a good safety record. This gives
impetus to the rationale for using adenoviruses as vectors for
human use. Michel Perricaudet (Paris) outlined the general
strategies behind the current generation of vectors, which
again depend heavily on methodology that has been in
laboratory use for a number of years. The basic design
renders the vector replication incompetent by deleting the
essential El region. Expression of this region is a prerequisite
for expression of the rest of the viral genome, and thus an
El-deficient recombinant should express only the therapeutic
gene of interest when delivered to the target cell. The recom-
binants themselves are constructed and propagated in cells
that stably express the El region, thus allowing virus stocks
to be prepared. In addition to the El deletion, extra space
for the insertion of foreign genes can be generated by
deleting the E3 region, which has been demonstrated to
be non-essential for growth in cell culture. Alan Smith
(Framingham) outlined an alternative strategy in which,
along with El, portions of the E4 region are deleted, leaving
only the E4 open reading frame 6 intact. These vectors grow
well, although the full potential of vectors containing simul-
taneous deletions in E1, E3 and E4 has yet to be explored.
Ken Berns (New York) described adenovirus-associated
virus (AAV). This small human parvovirus can replicate only
in the presence of adenovirus or herpes simplex to provide
replicative helper functions. It has found some utility as a
vector and has a number of attractive features, including lack
of disease associations or superinfection immunity, ability to
infect different types of cells and the ability to infect non-
dividing cells. It has a foreign DNA capacity of about 5 kb.
In the absence of helper virus, AAV and AAV vectors integ-
rate into the host genome at a limited number of sites,
reducing the probability of random, deleterious insertional
mutagenesis. Thus, like retroviruses, they lead to persistence
of the introduced gene in an integrated state. They can
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occasionally exhibit high transduction frequencies of the
order of 50-80%.
Diseases that involve cells of the nervous system (e.g.
neurodegenerative diseases) are currently receiving increased
attention. Herpes simplex virus (HSV) is an attractive vector
for neurological targeting since it naturally establishes latency
in neurons of the peripheral nervous system with the con-
comitant expression oflatency-associated transcripts and loss
of lytic functions. Joe Glorioso (Pittsburgh) recounted his
team's attempts to exploit these features as a means of
developing brain delivery systems. Two major hurdles have
initially to be overcome: (1) viral cytotoxicity and (2) per-
sistence of foreign gene expression. The extensive molecular
genetic knowledge of HSV has allowed significant progress to
be made in addressing the first problem by the use of virus
deletion mutants and appropriate complementing cell lines
coupled with further deletions in some ofthe large number of
genes known to be non-essential for growth in vitro. Several
approaches to overcome the difficulty of obtaining persistent
gene expression have been tried. One promising solution
appears to be the use of a recombinant yeast GAL4-VP16
fusion gene that is capable of sustained activation by transac-
tivation of its own promoter.
However, viruses are not the only means of transferring
genes to target tissues, although they can be used as acces-
sory agents in some other forms of delivery. One such ins-
tance is the receptor-mediated gene delivery system described
by Matt Cotten (Vienna). This consists of the DNA to be
transfected, condensed with a polycation (e.g. polylysine),
inclusion of a cell receptor-recognising component (e.g. trans-
ferrin) and streptavidin. Chemically inactivated, biotinylated
adenovirus particles are bound to the complex via the strep-
tavidin-biotin interaction and provide an endosome disrup-
tion activity required for exit of the complex from
endosomes. The transfection process appears to be efficient
and, since the DNA is not subject to the size constraints
imposed by a viral vector system, can be employed to trans-
fer large segments of genetic information. In addition varia-
tion of the cell-binding agent offers the prospect of a degree
of cell targeting.
A second non-viral method of gene delivery, liposomes,
was discussed by Bob Williamson (London). The major
advantages of this approach are the apparent lack of foresee-
able hazard as compared with viral delivery systems and,
again, the absence of size constraints on the sequences which
can be delivered. On the other hand, relatively poor transfec-
tion efficiency compared with virus systems means that the
amounts of DNA which must be incorporated are large.
Secondly since the transfected DNA is not integrated into the
genome, expression is likely to be short lived. Also, the
potential toxicity of liposomes has not yet been fully
evaluated. Animal model systems indicate that various for-
mulations of liposomes are effective, when used either
topically or after nebulisation, at introducing gene sequences
which can be expressed into cells lining the lung airways.
Recently this has been extended to a liposome-mediated gene
transfer trial for cystic fibrosis in humans.
A second human trial aimed at correcting the cystic
fibrosis (CF) defect was described by Alan Smith. In vitro
experiments demonstrated that relatively low multiplicities of
infection of CF cells in culture by a recombinant adenovirus
would correct both the fluid transport and electro-
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physiological defects of the cells. A trial was devised whereby
a small area of the nasal epithelium was infected with the
recombinant. Expression of the gene and correction of
electrophysical defects in the treated cells was demonstrated.
Recombinant adenovirus has also been used in a mouse
model ofmuscular dystrophy. Perricaudet described a recom-
binant containing a 6.3 kb Becker-like dystrophin cDNA
driven by the Rous sarcoma virus (RSV) promoter. A single
intramuscular injection into 5- to 9-day-old dystrophin-
deficient mdx mice resulted in expression of the dystrophin
gene within the muscle cells for at least 6 months. In
addition, the treated muscles were protected against
degeneration.
An alternative ex vivo approach for muscular dystrophy,
that of genetically correcting and retransplanting myogenic
stem cells, was discussed by Terry Partridge (London). The
attraction of this approach is that progressive repopulation
of dystrophic muscle by the transduced myoblasts might
eventually lead to genetic correction of whole muscle groups,
circumventing one of the current problems with in vivo gene
therapy of muscular dystrophy, namely that the extent of
genetic correction seen in a muscle is generally limited to a
small area around the site of administration of the
therapeutic agent. Using a dystrophic mouse model he pres-
ented some evidence for such a primitive muscle progenitor
cell capable of in vivo reconstitution and phenotype correc-
tion, and this approach may prove of some benefit in treating
the major skeletal muscle groups.
To facilitate long-lived correction of a genetic defect it will
be advantageous to target stem cells. Chris Potten (Man-
chester) defined stem cells as self-renewing, proliferative cells
with a large division potential capable of producing many
progeny which may differentiate in a variety of ways. In vitro
manipulation of stem (or at least very primitive progenitor)
cell populations has proved possible for a number of systems,
including haemopoietic, gut and muscle tissues. Ron McKay
(NIH) described immortalised lines derived from nestin (a
neural 'stem cell'-specific gene) positive cells which may be
propagated in vitro, and when implanted into the developing
hippocampus differentiate in vivo both morphologically and
functionally and are synaptically integrated with the host
brain. Cells such as this may prove useful targets for genetic
therapy of brain disorders. However, there are difficulties in
working with unimmortalised stem cells. These include their
identification, targeting, small numbers, accessibility and slow
cycle times (or even quiescence).
Wolfram Ostertag (Hamburg) discussed two areas which
restrict the efficiency of retroviral-mediated gene transfer into
haemopoietic stem cells. The first concerns the need to main-
tain the number and quality of progenitor cells in explanted
material. Although cocktails of soluble growth factors may
expand target cell populations, a net differentiative effect is
often seen. Co-culture of target cells with stroma in the
absence of added factors was found to be the best method of
maintaining the quality of stem cells. The use of long-term
bone marrow cultures provides just such conditions and may
facilitate manipulation of haemopoietic stem cells (Leslie
Fairbairn, Manchester).
A further issue is development of retroviral vectors suitable
both for high-titre infection of stem cells and maintenance of
gene expression in their progeny. Ostertag demonstrated the
value offorced retroviral passage in the selection ofbeneficial
mutations, such as those which overcome the down-
regulation of long terminal repeat (LTR) function found in
primitive cells. The application of this technique to recom-
binant retorviruses promises further increases in the efficiency
and repertoire of retroviral vectors.
For many applications it is desirable to direct the expres-
sion of introduced genes to a specific subset of the recipient
population. In this respect, studies of transcriptional control
reported by Dan Tenen (Boston) and Frank Grosveld (Rot-
terdam) provided indications of the multiple levels at which
transcriptional selectivity may be influenced. Tenen described
the involvement of the PU.1 and SPI transcription factors in
directing the macrophage-specific expression of the CD1lb
and macrophage colony-stimulating factor (M-CSF) receptor
genes. It is hoped that regulatory elements of this type will be
invaluable in modulating the expression pattern of linked
therapeutic genes. However, we still know very little about
the establishment of gene transcription patterns during the
developmental processes which will be-relevant to many gene
therapeutic approaches. The presentation of Grosveld des-
cribed multiple levels at which the transcription patterns of at
least some endogenous genes are determined. Studies on the
developmental regulation of the beta-globin gene locus have
demonstrated a requirement for regulatory elements a large
distance from their target genes. These 'locus control regions'
(LCRs) consist of dispersed groups of transcription factor
binding sites, and are absolutely required to establish high-
level, specific transcription in developing cells. The activity of
regulatory regions located close to each gene of the beta-
globin cluster is dependent upon interaction with LCR
elements in a competitive manner. There is much still to learn
about the involvement of long-range regulatory interactions
and higher order chromatin structure in the establishment
and maintenance of tissue-specific gene expression. Further-
more, it seems likely that the combination of elements
required to achieve tissue-specific and prolonged expression
of some genes may lead to a need to use larger therapeutic
DNA sequences than can be accommodated in a retrovirus.
An obvious role for gene therapy is in the treatment of
inherited genetic disorders, many of which are caused by
single-gene defects. Indeed, the first therapeutic use of gene
therapy was for the rare autosomal recessive disorder, severe
combined immune deficiency (SCID), a consequence of
defects in the gene encoding the enzyme adenosine deaminase
(ADA) and which results in lymphopenia and deficits in both
humoral and cellular immunity. Jay Ramsay (NIH) described
these first treatments, which used retroviral gene transfer of a
normal human ADA cDNA into peripheral T cells. The two
patients in the trial have elevated ADA levels in peripheral
blood lymphocytes which have been sustained for up to 12
months following infusion. Functionally, their immune
systems show significant reconstitution with decreased fre-
quencies and severities of infectious diseases and improved
responses to immune challenges. These encouraging data
have led to the development of strategies for haemopoietic
stem cell gene therapy of this disease to achieve long-term
improvement of immune function without the need for con-
tinued reinfusion.
Haemopoietic stem cell gene therapy is also the method of
choice for other inherited disorders of the blood system.
Mike Antoniou (London) addressed the problems associated
with a gene therapy approach to the haemoglobinopathies (a-
and P-thalassemia, sickle cell anaemia). Although, given the
complexities associated with controlled expression of globin
genes, a gene therapeutic answer to these diseases may still be
a long way off, the widespread nature of the haemoglobino-
pathies (compared with the relative rarity of, for example,
ADA-SCID) makes a powerful case for substantial tech-
nological investment in their treatment.
The haemopoietic stem cell lends itself as a target for gene
therapy of diseases whose effects are not limited to cells of
the haemopoietic system. Thus, where a defective gene
encodes a secreted protein, expression and subsequent secre-
tion of a product by haemopoietic cells may result in allevia-
tion of disease. Examples of this are the lysosomal storage
disorders, in which lack of one enzyme leads to the
accumulation of glycosaminoglycans in the lysosomes of cells
and to a range of clinical effects. Because enzyme secreted by
one cell can be sequestered by non-expressing cells and
targeted to their lysosomes, the cells of the haemopoietic
system can act as producers of enzyme for uptake by other
tissues. Furthermore, the ability of tissue macrophages to
enter the brain means that this approach might circumvent
the blood-brain barrier and hence effect transfer of enzyme
to neurons and other cells of the central nervous system.
Allogeneic bone marrow transplantation has already been
used in this context for Hurler's syndrome, and this approach
is able to alleviate many aspects of the disease phenotype,974 L.J. FAIRBAIRN et al.
including neurological effects. Fairbairn presented work
showing that long-term (30 weeks) expression and secretion
of the enzyme M-L-iduronidase and apparent correction of
disease phenotype in vitro is possible after retroviral gene
transfer to bone marrow cells from patients with Hurler's
syndrome.
When there is no significant neurological involvement in a
disorder, and thus no need for delivery of product across the
blood-brain barrier, other tissues also lend themselves as
targets for transfer of genes encoding secreted proteins.
Oliver Danos (Paris) described such an approach for another
lysosomal storage disorder, mucopolysaccharidosis (MPS)
VII (Sly syndrome). Primary fibroblasts from MPS VII mice
were transduced with a retrovirus expressing human 1B-
glucuronidase, embedded in a collagen lattice and reim-
planted. Danos and colleagues saw vascularisation of the
neo-organ, accumulation of enzyme in some tissues and cor-
rection of the storage lesions in those tissues. Scaled-up
experiments using a dog model of the disease suggest that
this approach is feasible for larger animals. In a similar
approach, Inder Verma (San Diego) and colleagues have
used gene transfer into myoblasts in developing a gene
therapy approach to the clotting disorders. They found that
myoblasts can be readily infected in vitro with retroviruses,
and that following fusion of the myoblasts in vivo to form
myotubes expression of the foreign protein (in this case
human factor IX) was maintained for up to 15 months in
recipient mice without any apparent adverse effects, raising
genuine prospects for gene therapy of these diseases. Both
Verma and Danos noted that in order to maintain expression
in post-mitotic cells (fibroblasts and myotubes) it was neces-
sary to use promoters other than the retroviral LTR. Thus
the use of a phosphoglycerate kinase promoter for fibroblasts
and a muscle creatine kinase promoter for myoblast gene
therapy was necessary for sustained expression. This restric-
tion of expression, which may reflect tissue-specific expres-
sion of transcription factors, will be of importance to other
strategies aimed at using such cells for exocrine gene therapy,
particularly where it may be desirable (as in the case of
insulin gene therapy for diabetes) to obtain modulation of
expression in response to physiological changes.
Diseases which are due to acquired genetic defects (notably
cancers) are also tempting targets for genetic therapy. There
are treatment regimens available for most tumours, which
give either a full or partial cure of disease in a fraction of
patients that may be a large proportion of those presenting
with disease or a depressingly low one. As Howie Scarffe
(Manchester) pointed out, the wealth of knowledge acquired
to date about the nature of cancer has not yet led to a
marked improvement in clinical results, and most efficacious
chemotherapeutic treatments (particularly those of childhood
cancer, lymphoma and leukaemia) have been arrived at in an
empirical and pragmatic way. Improvements in support care
of patients, refined methods of surgery, radiotherapy and
clinical use of haemopoietic growth factors or bone marrow/
peripheral blood progenitor cells transplants have led to
decreased patient morbidity and mortality. Nevertheless the
rate of cure of some of the most common adult cancers (e.g.
breast and colon) has remained largely unchanged. He ended
with a call for novel approaches to cancer treatment.
David Lane (Dundee) discussed the possibility of using one
of the genetic defects of a tumour as a target for genetic
therapy of disease. A common feature of many different
tumours is loss of function of a specific gene product, and a
number of these commonly lost genes are tumour suppres-
sors, of which the retinoblastoma and the p53 genes are the
best-known examples. Restoration of wild-type p53 function
to tumour cells can lead to dramatic growth-inhibitory or
lethal effects. A further feature of normal p53 is that it is
markedly more stable in tumour cells than in normal cells.
Thus its expression is well tolerated by normal cells, whereas
it accumulates in tumour cells, promoting a profound growth
arrest or cell death via apoptosis. Thus it might prove possi-
ble to use p53 gene transfer in a therapeutic situation to
obtain arrest or decline of a tumour while the effects upon
fortuitously transfected normal cells could prove minimal.
One of the critical steps in the development of a tumour
may be the ability of the abnormal cells to escape immune
surveillance. As a result, tumour cells are often poor
immunogens and attempts are being made to modulate their
immunogenicity by inducing them to express and secrete
cytokines which can stimulate cells of the immune system.
Mary Collins described comparisons of the ability of
interleukin 2 (IL-2), IL-4 and y-interferon gene expression in
tumour cells to induce rejection of admixed unmodified
tumour cells. In their system, y-interferon offered the best
hope of tumour rejection compared with IL-2, which has
proved efficacious in other animal model systems. However,
the acid test, that of treatment of tumour in situ, is yet to be
done. In a rat model of metastatic disease, Collins showed
the efficacy of IL-2-secreting tumour cells in preventing the
development of secondary tumours following excision of the
primary lesion. This approach may hold real hope for
cytokine gene therapy in an adjuvant role.
A major problem with chemotherapeutic approaches to
cancer treatment is the dose-limiting toxicity of most anti-
tumour agents, and approaches to reduce the cytotoxic
effects in normal tissues while maintaining the sensitivity of
tumour cells to cytotoxic agents would be useful. A number
of genes are available which confer resistance to cytotoxic
agents. Massimo Gianni (Milan) and Joe Rafferty (Man-
chester) described similar approaches using different resis-
tance genes. Gianni discussed the efficacy of the human
aldehyde dehydrogenase (ALDH-J) gene to confer resistance
to the alkylating agent cyclophosphamide. K562 cells induced
to express ALDH-J are 3-5 times more resistant to cyclo-
phosphamide than controls. The product of the 06-alkyl-
DNA alkyltransferase (ATase) gene confers resistance to
chemical alkylating agents, a large family ofcytotoxics, many
of which are used clinically. Rafferty showed that expression
and persistence of a transferred ATase gene in primary
murine haemopoietic cells could be achieved via retroviral
gene transfer. ATase expression conferred resistance to the
cytotoxicity of N-methyl-N-nitrosourea (MNU), suggesting
such an approach could be used to alleviate secondary tox-
icity following treatment with alkylating agents such as bis-
chloroethylnitrosourea (BCNU). Many tumours also express
ATase, accounting for their relative resistance to alkylating
agent-induced death. Inhibitors of ATase, such as 06_
benzylguanine (BzG), can reduce this resistance, but also
affect normal tissues. Retroviral gene transfer of the E. coli
ATase (ada), which is more resistant to BzG than the
endogenous ATase, into sensitive normal tissues raises the
possibility of specifically increasing the resistance of bone
marrow (or lung, etc.) to a chemotherapeutic regimen while
increasing the sensitivity of tumour cells. When designing
gene therapy approaches to haemopoietic toxicity, considera-
tion should be given to the target cell population which needs
to be protected. Perhaps stem cells are relatively resistant to
alkylating agents owing to their proliferative quiescence and
the most at-risk populations of haemopoietic cells are the
progenitor cells. If so, peripheral blood progenitor cells,
which can be mobilised by chemotherapy and cytokines, and
which are actively cycling and therefore targets for recom-
binant retroviruses, may be the population to which this
approach may be most appropriate. Gianni presented
evidence that under appropriate circumstances nearly 100%
of colony-forming cells from the peripheral blood of a
chemotherapy/cytokine-treated patient may be infected with
a retroviral vector.
An alternative to protecting sensitive normal tissues from
the cytotoxic effects of anti-cancer drugs is to avoid their
exposure to such agents. One approach to this would be to
modify tumour cells such that they specifically activate an
otherwise harmless prodrug to generate the cytotoxic
derivative only inside the tumour cell. Karol Sikora
(London) described the use of a c-erbB-2 promoter to drive
expression of a cytosine deaminase gene in transduced
tumour cells. Transcription of c-erbB-2 is much greater in
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cription factor which binds to a response element within the
c-erbB-2 promoter. Thus it may prove possible to achieve
high levels of cytosine deaminase in some tumour cells com-
pared with normal tissues. Since cytosine deaminase converts
5-fluorocytosine (5-FC) to the cytotoxic agent 5-fluorouracil,
it follows that such cells would be selectively killed after
administration of 5-FC to a patient.
In a similar approach, Zvi Ram and colleagues (NIH) have
used retroviruses carrying the herpes simplex virus thymidine
kinase (HStk) gene to express this gene in tumour cells. In
animals models of brain tumours, they were able to obtain
transfer and expression of HStk in the cycling neoplastic cell
population after direct injection of retroviral producers into
the tumours. The quiescent normal cells of the brain
appeared largely unaffected, and following treatment with the
prodrug pre-established tumours were seen to regress. Subse-
quently a clinical trial treating eight patients with unrespon-
sive, progressive malignant brain tumours has been initiated.
In five of the eight patients treated some evidence of an
anti-tumour response (decrease in tumour size or changes in
tumour consistency) was seen. Although this trial was not
intended as a full therapeutic treatment but was designed to
evaluate toxicity and the potential for anti-tumour activity in
vivo in humans, the data thus far look extremely promising
with anti-tumour effects being achieved without any
treatment-associated toxicity being observed. Based on data
from animal models, it is unlikely that all the tumour cells
which were killed were transduced with the HStk retrovirus.
This phenomenon, known as the bystander effect, in which
induction of death in some cells leads to death of surround-
ing ones, is not well understood. However, it is likely that a
number of effects, including transfer of activated drug via
gap junctions or by intercellular diffusion, destruction of
tumour microcirculation and activation of an immune res-
ponse, may contribute to the cell death seen.
The meeting ended with a session devoted to regulatory,
ethical and safety considerations. Sir Cecil Clothier (Chair-
man of the first government-appointed committee to examine
the implications of gene therapy) pointed out that all
attempts to restrain or confine the progress of science are
contrary to man's nature and therefore will fail. However,
there is always the temptation to abuse scientific
developments, the motive usually being profit. The more
blatant of such abuses drive society to legal regulation.
Clothier asserts that generally new technology is available
only to a small number of individuals who are of high
integrity but that, as time goes by, technology advances and
becomes more widely available, at which time the abusers
move in. Therefore regulation can and should be voluntary
at first, but once the scope for abuse is determined legal
controls should be applied.
John Harris (Manchester) considered ethical issues, in par-
ticular the distinction between somatic and germ-line
therapy. The general perception had been that these forms of
therapy are fundamentally different from an ethical point of
view and should be regulated differently. However Clothier
clarified his committee's thesis that rather than being an
ethical issue, the current distinction between the two was on
the grounds of current lack of availability of knowledge of
the consequences of gene therapy and that as more became
known we would be better able to contemplate germ-line
therapy.
Tony Meager (Potter's Bar) concluded the presentations
with a sobering enumeration of the extensive requirements of
safety regulatory authorities' demands for vector and product
characterisation, stringent testing for a large number of
undesirable agents, criteria for containment and operating
standards of production facilities and the need for comp-
rehensive documentation of reagents and procedures.